BASEL, Switzerland, Nov. 29, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating the root causes of rare conditions, today announced that the European Commission has granted Orphan Drug Designation…
BASEL, Switzerland, Oct. 9, 2018 /PRNewswire/ — Therachon AG (“Therachon”), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the acquisition of GLyPharma Therapeutic Inc. (“GLyPharma”) for…
BASEL, Switzerland, August 9, 2018 – Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced it has completed a $60 million mezzanine financing led by Novo Holdings and…
BASEL, Switzerland, June 21, 2018 – Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced the start of “Dreambird,” a natural history study of children with achondroplasia, the…
BASEL, Switzerland, March 13, 2018 – Therachon AG, a clinical-stage biotechnology company focused on rare diseases, today announced it has appointed industry leader Aled Williams to the position of Chief Commercial…
